---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-001999"
form_type: "8-K"
ticker: "CNBX"
cik: "0001343009"
company_name: "CNBX Pharmaceuticals Inc."
filed_at: "2022-03-28T23:59:59+00:00"
generated_at: "2026-06-26T15:52:20.449878+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Cannabics Pharmaceuticals changes name to CNBX Pharmaceuticals, ticker unchanged

## Summary
- Name change effective March 28, 2022; stock continues trading on OTCQB under symbol CNBX.
- Name change reflects transformation to molecule-based drug development for colorectal cancer treatment.
- Company preparing Phase I/II clinical validation study for proprietary RCC-33 drug candidate.
- Stockholders need not exchange certificates; rights unaffected.

## SEC filing metadata
- accession: 0001683168-22-001999
- form_type: 8-K
- ticker: CNBX
- cik: 0001343009
- company_name: CNBX Pharmaceuticals Inc.
- filed_at: 2022-03-28T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1343009/000168316822001999/0001683168-22-001999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1343009/000168316822001999/cannabics_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-001999
- JSON: https://secwatch.observer/filing/0001683168-22-001999.json
- Plain text: https://secwatch.observer/filing/0001683168-22-001999.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.